Neuphoria Therapeutics Inc. (NEUP) financial statements and ratios from SEC XBRL: revenue $15.65M (TTM), net margin -2.4%, revenue growth -98.8% YoY, P/E 7.9. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $15.65M |
| Net Margin | -2.4% |
| Revenue Growth (YoY) | -98.8% |
| EPS Growth (YoY) | -101.4% |
| P/E Ratio | 7.9 |
| EV / EBITDA | 0.9 |
| Price / Book | 0.73 |
| Price / Sales | 1.38 |
| Altman Z-Score | -7.28 (distress) |
| Sector P/E (Healthcare) | 21.7 |
NEUP overview · NEUP earnings · NEUP KPIs · NEUP investor relations · NEUP ownership · NEUP peers · NEUP filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.